Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Sarepta Therapeutics Inc

SRPT ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: HOLD

Last Close

$18.10

▼ -1.74%

Market Cap $1.91B · Vol 569.89K

Key Metrics

P/E Ratio

58.60

FWD: 10.60

Market Cap

$1.91B

Small Cap

Div Yield

N/A

EPS Growth

+142.98%

YoY

RSI (14)

68.14

Momentum

Beta

0.26

vs Market

52W High

$25.30

28.46% below

52W Low

$14.69

23.21% above

Volume

569.89K

Avg 1.20M

P/B

1.98

Price-to-book

ROE

-53.47%

Return on equity

Free Float

95.07%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Sarepta Therapeutics Inc (SRPT) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SRPT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.87%

+0.78%

-3.10%

+1.74%

YTD

-15.89%

-10.84%

-84.13%

-77.36%

Financials & Valuation

TTM · Annual

Total Revenue	$2.20B
Net Income	$-713,410,000.00
Revenue Growth (YoY)	-34.34%
Gross Margin	69.21%
Operating Margin	-22.40%
Net Profit Margin	-32.45%
ROE	-53.47%
ROA · ROIC	-19.21% · N/A

P/E Ratio	58.60
Forward P/E (FY1)	10.60
PEG Ratio	N/A
P/S	0.98
P/B	1.98
P/FCF	N/A
EPS Growth	+142.98%
Outstanding Shares	105.63M

Technical Indicators

50-Day SMA	$16.99
200-Day SMA	$19.14
RSI (14)	68.14
Beta	0.26
52-Week High	$25.30
52-Week Low	$14.69

Volume Today	569.89K
Avg Daily Volume (30D)	1.20M
Relative Volume	0.48x
Volatility (10D)	48.55
Volatility (30D)	50.17
Free Float	95.07%

Analyst Consensus

HOLD

Current Price $18.10

Mean Target $22.51

52W Low$14.69 52W High$25.30

Current

Target

$14.69 $25.30

Current Analyst target

+24.36% upside potential · 25 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S6KJC6

ISINUS8036071004

CountryUnited States of America

Sub-IndustryIn-Vivo Diagnostic & Testing Substances

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

OBD.L Oxford Biodynamics PLC +0.00% LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% MRK Merck & Co Inc +0.21%

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.